14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
FUTU vs NMR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Futu Holdings Limited (FUTU) is the stronger overall head-to-head candidate over Nomura Holdings, Inc (NMR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FUTU carries a Unified Composite Score of 47.3/100 (HOLD) at $86.89 (8.6x Forward P/E, 66.7% operating margin), whereas NMR carries 44.5/100 (HOLD) at $9.34 (12.7x Forward P/E, 25.1% operating margin).
Technical & Structure Timing Caution: FUTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5); meanwhile NMR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FUTU vs NMR. Trailing 12-month operating profitability (FUTU 66.7% vs NMR 25.1%) and valuation multiples (FUTU 8.6x vs NMR 12.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Capital Markets value chain with $13.4B market capitalization and 66.7% operating margin.
OpEx & R&D Reinvestment27.4% of Rev ($838M)
90D Engineering Disclosures0 Published
NMR Moat ProfileScale & Operating Efficiency Moat
Capital Markets Operator
Competes within the Capital Markets value chain with $28.3B market capitalization and 25.1% operating margin.
OpEx & R&D Reinvestment52.3% of Rev ($7.77B)
90D Engineering Disclosures0 Published
Investor FAQ FUTU vs NMR Key Questions & Quantitative Answers
As of Nov 17, 2026, Futu Holdings Limited (FUTU) is the stronger overall head-to-head candidate over Nomura Holdings, Inc (NMR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FUTU carries a Unified Composite Score of 47.3/100 (HOLD) at $86.89 (8.6x Forward P/E, 66.7% operating margin), whereas NMR carries 44.5/100 (HOLD) at $9.34 (12.7x Forward P/E, 25.1% operating margin). Technical & Structure Timing Caution: FUTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5); meanwhile NMR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
FUTU leads the Growth & Scale pillar: FUTU posts +35.6% YoY revenue growth and +43.0% YoY earnings growth on $3.06B TTM revenue (94.1% gross margin, 66.7% operating margin), compared with NMR at +17.9% YoY revenue growth and +13.6% YoY earnings growth on $14.9B TTM revenue (77.4% gross margin, 25.1% operating margin). On trailing 12-month operating scale, FUTU generates $3.06B in USD-normalized revenue versus $14.9B for NMR. In operating R&D and SG&A reinvestment, FUTU deploys 27.4% of Rev ($838M) (0 90-day corporate R&D disclosures) versus 52.3% of Rev ($7.77B) (0 disclosures) for NMR.
FUTU screens cheaper on headline valuation multiples. FUTU trades at 8.6x Forward P/E, 9.5x Trailing P/E, N/M PEG, and 4.4x EV/Revenue (unreported cash flow margin), whereas NMR trades at 12.7x Forward P/E, 11.2x Trailing P/E, 0.81x PEG, and 1.9x EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FUTU (30.5% ROE) versus NMR (11.5% ROE) capital efficiency.
In options market volatility and institutional positioning, FUTU carries 49.3% implied volatility (20th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.79β · 49% Vol realized risk). By comparison, NMR carries 30.7% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.03β · 29% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.